Achieves critical regulatory milestones, positioning company as leading turnkey partner in booming hypochlorous acid sector to capture portion of growing $2.8B clean beauty market as industry shifts away from harsh chemical formulations Pure Aquaox logo Pure Aquaox logo TAMPA, Fla., July 11, 2025 (GLOBE NEWSWIRE) -- Full Alliance Group Inc. (OTC: FAGI) and its fifty one percent owned subsidiary, Aquaox Pure Solutions, LLC, announce two pivotal regulatory achievements that position the company at the fore ...

Key Takeaways COO grew EPS 14% and expanded operating margin to 24.9% despite macro challenges. Strong gains for COO's MyDay lenses and surgical devices offset weaker fertility and Asia demand. Inventory destocking and tariff risks may pressure COO's revenues and EPS into in fiscal 2026. The Cooper Companies, Inc.’s (COO) strategic investments in innovation and its diversified product base support long-term growth. However, near-term macro and inventory challenges, particularly in fertility and global con ...

Core Insights - Polyrizon Ltd. announced positive preclinical results for its hydrogel-based Trap & Target (T&T) platform, indicating effective drug delivery to the upper nasal cavity, which is crucial for central nervous system (CNS) applications [1][4] Group 1: Study Results - The study, conducted with the University of Parma, showed that Polyrizon's hydrogel formulation achieved over 60% preferential accumulation in the middle and upper turbinates, enhancing nose-to-brain transport [3] - The results suggest potential applications for CNS indications, such as opioid overdose treatment and seizure management, where rapid brain access is critical [3][4] Group 2: Technology Validation - The CEO of Polyrizon emphasized the validation of the T&T technology's ability to achieve localized deposition in favorable nasal regions, which could lead to new therapies for acute neurological and psychiatric conditions [4] - The hydrogel demonstrated consistent delivery to upper nasal segments while maintaining favorable handling characteristics, supporting further preclinical development [4] Group 3: Future Plans - Polyrizon plans to validate these preclinical results in animal models and initiate safety studies as part of its translational roadmap for the T&T technology [5]

Raanana, Israel, May 23, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced that it has received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), stating that based on its review of the Company’s public filings with the Securities and Exchange Commission (the “SEC”), its staff has determined to delist ...

Core Insights - Polyrizon Ltd. has announced significant results from ex vivo studies demonstrating the mucoadhesive strength and extensive nasal surface coverage of its proprietary formulation platform [1][2][3] Group 1: Study Findings - The studies were conducted in collaboration with Prof. Fabio Sonvico's laboratory, using excised rabbit nasal mucosa to simulate human nasal tissues [2] - Advanced ex vivo studies showed that Polyrizon's formulation spreads rapidly and uniformly across the nasal mucosa, forming a consistent surface layer [3] - Mucoadhesion testing indicated that the formulation maintains strong attachment to nasal tissue, even under conditions simulating physiological nasal fluid flow, supporting prolonged efficacy [3][4] Group 2: Product Overview - Polyrizon specializes in developing innovative medical device hydrogels delivered as nasal sprays, which create a hydrogel-based barrier in the nasal cavity to protect against viruses and allergens [5] - The proprietary Capture and Contain (C&C) hydrogel technology is designed to function as a "biological mask" and is being further developed for enhanced bioadhesion and prolonged retention for drug delivery [5] - An additional technology, Trap and Target (T&T), is in pre-clinical development focused on nasal delivery of active pharmaceutical ingredients [5]

Core Insights - CooperCompanies published its 2024 Sustainability Report, highlighting initiatives aimed at fostering positive change for people and the planet, along with updated sustainability performance data [1][2] Group 1: Sustainability Initiatives - In 2024, CooperCompanies focused on reducing its plastic footprint, achieved several sustainability certifications, and made significant investments in employee learning and development programs [2] - The report aligns with the Sustainability Accounting Standards Board (SASB) Standards, a recognized framework for evaluating sustainability performance [3] Group 2: Company Overview - CooperCompanies operates through two main business units: CooperVision, a leader in the contact lens industry, and CooperSurgical, which focuses on fertility and women's healthcare [4] - The company is headquartered in San Ramon, California, employs over 16,000 people, sells products in more than 130 countries, and positively impacts over 50 million lives annually [4]

NEXGEL (NXGL) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Company Participants Valter Pinto - Managing DirectorAdam Levy - CEO, President & DirectorJoseph F. McGuire - CFOEric Ramos - Student Portfolio Manager Conference Call Participants Naz Rahman - AnalystNone - Analyst Operator Good afternoon. I will be your conference operator today. At this time, I would like to welcome everyone to NextGel's First Quarter twenty twenty five Financial Results Conference Call. I will now turn the call over to Walter ...

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $2,810,000, representing a 121% increase year over year compared to $1,270,000 in Q1 2024 [5][21] - Gross margins normalized to 42.4%, compared to 37% in Q4 2024 and 43.6% in Q3 2024 [5][22] - EBITDA loss narrowed to negative $540,000 from negative $840,000 in the same period last year [6][23] - Net loss for Q1 2025 was $710,000, down from a net loss of $850,000 in Q1 2024 [23] Business Line Data and Key Metrics Changes - Contract manufacturing revenue increased by 58% year over year, driven by demand from existing customers and new partnerships [5] - Consumer branded products revenue surged by 189% year over year, significantly boosted by the addition of Silly George [5] - The company expects continued growth in both contract manufacturing and consumer products, with a robust pipeline for 2025 [8][11] Market Data and Key Metrics Changes - The company is seeing increased interest in U.S.-made gels due to potential tariff impacts, which may enhance competitiveness against imported products [19] - There is a growing market for hydrogel applications, particularly in laser hair removal, with significant interest from major companies [42] Company Strategy and Development Direction - The company plans to expand its product lines, including new offerings for MetaGel and Cancoderm, and is transitioning Silly George into a broader beauty brand [12][13] - The partnership with Stata is progressing well, with plans for additional product launches in 2025 and 2026 [14] - The company is strategically managing cash and R&D to ensure high ROI while pursuing growth opportunities [14] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about achieving $13,000,000 in revenue and cash flow positivity in 2025 despite external challenges [20] - The company is monitoring tariff situations closely and is prepared to adjust manufacturing strategies if necessary [16][19] - Management expressed confidence in the growth potential of their products and the overall market, despite uncertainties in the broader economic environment [60] Other Important Information - The company has a cash balance of approximately $1,190,000 as of March 31, 2025 [23] - The company has 7,654,537 shares of common stock outstanding as of May 13, 2025 [23] Q&A Session Summary Question: How much revenue was expected from AbbVie, and does the delay affect guidance? - Management indicated that not much revenue was baked in from AbbVie, so the delay should not significantly impact the $13,000,000 projection [25][26] Question: Can you provide details on the product launch with Stata? - The first product is Histosol, a digestive enzyme, with plans for additional digestive enzymes in the future [30] Question: Is there a seasonal improvement expected for Silly George? - Management expects seasonal growth, especially with new product launches planned for Q3 and Q4 [61][62] Question: Will transitioning manufacturing to Texas impact other business lines? - The company has built a new clean room with enough capacity to accommodate potential shifts in manufacturing [35][36] Question: Will the company survive on current cash reserves until EBITDA positive? - Management believes they can manage with current cash reserves until reaching EBITDA positivity [66]

Raanana, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, recently announced the initiation of preclinical studies for intranasal Benzodiazepines (BZDs), a first-line treatment for acute repetitive seizures (ARS) and status epilepticus, using its proprietary drug delivery platform. According to the World Health Organization (WHO), epilepsy is a neurolo ...

Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the first quarter 2025, after the market close on May 13, 2025. Following the release of its financial results, the Company will host a conference call at 4:30 p ...